A Phase 1b/2 Study of PCM-075 in Combination With Either Low-Dose Cytarabine or Decitabine in Subjects With Acute Myeloid Leukemia (AML)

Trial Profile

A Phase 1b/2 Study of PCM-075 in Combination With Either Low-Dose Cytarabine or Decitabine in Subjects With Acute Myeloid Leukemia (AML)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Apr 2018

At a glance

  • Drugs PCM 075 (Primary) ; Cytarabine; Decitabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors TrovaGene
  • Most Recent Events

    • 18 Apr 2018 Results describing preliminary patient data and biomarker assays used to evaluate target engagement presented at the 109th Annual Meeting of the American Association for Cancer Research
    • 17 Apr 2018 Results published in the TrovaGene Media Release
    • 12 Apr 2018 According to a TrovaGene media release, data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top